04/27/2017

FDA has expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma.

The FDA has expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.

For more information, click here.